Medtronic’s Q3 numbers top estimates

Medtronic (NYSE:MDT) today beat the consensus forecast with its fiscal 3rd-quarter results, despite a -25% profit slide, sending shares up slightly in pre-market trading.

The Fridley, Minn.-based medical device giant posted profits of $821 million, or 59¢ per share, on sales of $7.28 billion for the 3 months ended Jan. 27. That’s a -25.0% bottom-line slide on sales growth of 5.0%, compared with Q3 2016.

Adjusted to exclude 1-time items, earnings per share were $1.17, 6¢ ahead of the consensus on Wall Street, where analysts were looking for sales of $7.22 billion.

“In Q3, we achieved solid results across all of our business groups and geographies. At the same time, we produced meaningful operating profit growth based largely on our synergy programs from the Covidien integration, as well as our focus on operating excellence initiatives,” chairman & CEO Omar Ishrak said in prepared remarks. “We remain confident in our ability to deliver mid-single-digit constant-currency revenue growth and double-digit constant-currency EPS growth, not only in our current fiscal year, but also into the future. With our differentiated growth platforms and leadership in strong healthcare growth markets, we believe we are well positioned to create long-term, dependable value for our shareholders.”

Medtronic said it still expects to report adjusted EPS of $4.55 to $4.60 on adjusted sales growth in the mid-single-digit range. Fiscal 4th-quarter revenue growth is pegged at the lower half of the mid-single-digit range, the company said.

The post Medtronic’s Q3 numbers top estimates appeared first on MassDevice.

from MassDevice http://ift.tt/2kUxvCk